|
📅 Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products(CRCG)
|
|
39
|
3626
|
May 2, 2025
|
|
HSA Industry Training Workshop 2024 - Management of Nitrosamine Impurities in Therapeutic Products
|
|
2
|
339
|
April 29, 2025
|
|
FDA Generic Drugs Forum - Bioequivalence Approaches
|
|
2
|
1062
|
April 22, 2025
|
|
Generic Drugs Forum (GDF) 2025
|
|
5
|
1038
|
April 19, 2025
|
|
:brazil: Lhasa Brazil Symposium: Aligning Pharma & Regulatory Standards Globally :brazil:
|
|
0
|
160
|
April 3, 2025
|
|
Dr. Andrew Teasdale on the recent updates on Nitrosamine Impurities - Virtual Workshop
|
|
1
|
702
|
March 15, 2025
|
|
Nitrosoureas and beyond: What to do when the CPCA doesn’t apply
|
|
0
|
410
|
March 5, 2025
|
|
🇲🇽 Boot Camp de Nitrosaminas 13/14 Marzo en CDMX
|
|
54
|
1263
|
February 27, 2025
|
|
Free Webinar - Detecting unexpected nitrosamine contamination
|
|
1
|
401
|
February 13, 2025
|
|
FREE Lhasa Webinar | Nitrosaminas en el horizonte: ¿Está preparado? 🇲🇽
|
|
1
|
307
|
January 22, 2025
|
|
SCIEX Webinar: Unlocking precision: nitrosamine and NDSRI analysis(16.1.2025 10:30 CET)
|
|
0
|
399
|
January 12, 2025
|
|
👨💻 FDA-CRCG NDSRI Workshop
|
|
2
|
1577
|
January 10, 2025
|
|
CAPRA 2024 Pharmaceutical SYMPOSIUM PRESENTATIONS & MATERIALS
|
|
0
|
397
|
December 25, 2024
|
|
Free webinar: From Ambiguity to Action, The FDA's New Nitrosamine Guidance
|
|
1
|
643
|
December 2, 2024
|
|
Small Nitrosamines in excipeints
|
|
11
|
629
|
November 21, 2024
|
|
📅 Analytical challenges and the effective management of nitrosamines: The evolving landscape of NDSRI analysis
|
|
3
|
656
|
October 30, 2024
|
|
AAPS PharmSci360 -Nitrosamines
|
|
13
|
753
|
October 22, 2024
|
|
Royal Australian Chemical Institute
|
|
0
|
89
|
September 26, 2024
|
|
57th Congress of the European Societies of Toxicology (EUROTOX 2023)
|
|
2
|
722
|
September 24, 2024
|
|
Facing Up to the New Nemesis of Pharma: Nitrosamines What’s going on with nitrosamines in pharmaceutical products? Naiffer Romero, Principal Scientist at the US Pharmacopeia walks us through frequently asked questions
|
|
0
|
237
|
September 23, 2024
|
|
9th Impurities: Genotoxic, Nitrosamine, & Beyond Summit
|
|
0
|
515
|
September 18, 2024
|
|
PMDA-USP Workshop - Nitrosamines Track
|
|
2
|
574
|
September 17, 2024
|
|
FDA-CDER and HESI | Nitrosamine Ames Data Review and Method Development Workshop
|
|
1
|
291
|
September 17, 2024
|
|
Potential Topic for an event concerning obtaining the right level of Nitrosamine Risk Assessment information from your CMOs
|
|
22
|
1735
|
September 5, 2024
|
|
📅 FDA - CRCG Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products -Event
|
|
1
|
1023
|
August 14, 2024
|
|
IPEC Webinar on the role of excipients in determine N-nitrosamine risks
|
|
3
|
499
|
July 24, 2024
|
|
Classification of potentially mutagenic impurities under the ICH M7 guideline -Event
|
|
0
|
420
|
July 23, 2024
|
|
Nitrosamine in vivo mutagenicity workshop
|
|
10
|
837
|
July 22, 2024
|
|
Nitrosamine impurities in medicines (presented at the ARCS Annual Conference 2024)
|
|
12
|
1246
|
July 17, 2024
|
|
USP India - Nitrosamines panel discussion at USP Science Conclave
|
|
0
|
378
|
July 10, 2024
|